Soblidotin
Also known as: Auristatin PE, Dolastatin 10 analogue, Soblidotin, TZT-1027, TZT‑1027
Source Soblidotin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Soblidotin (TZT‑1027) is a synthetic analog of the marine peptide dolastatin 10. It acts as a potent antimitotic agent by disrupting microtubule dynamics and has been evaluated in early‑phase clinical trials for solid tumours.
Mechanism of Action
binds to tubulin at the Vinca site, inhibiting microtubule polymerization and causing cell‑cycle arrest
Routes of Administration
Goals & Uses
- Solid tumor oncologyOncologyModerate
- Non-small cell lung cancer treatmentOncologyModerate
- Antitubulin antineoplastic activityOncologyModerate
- ADC payload candidateOncologyLow
- Soft tissue sarcoma treatmentOncologyModerate
Contraindications
- Severe peripheral neuropathyNeurotoxicityHigh
- Severe hepatic impairmentOrganHighLiver function concerns
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- hypersensitivity to soblidotin or excipientsAllergyModerate
Adverse Effects
- Peripheral neuropathyNeurologicalUncommon
- AlopeciaDermatologicCommonHair loss
- ConstipationGastrointestinalUncommonReduced bowel frequency or difficulty passing stool
- Nausea/vomitingGastrointestinalCommon
- NeutropeniaHematologicCommonLow neutrophil count
- FatigueGeneralCommonLow energy or tiredness
Drug Interactions
- Other antineoplasticsModerate
- CYP3A4 inhibitors (e.g., ketoconazole)Moderate
- Other myelosuppressive agentsHigh
Population Constraints
- PregnancyReproductive SafetyAbsolute
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveAbsolute
- Patients with pre-existing neuropathyNeurologicRelative
Regulatory Status
- European UnionInvestigationalClinical trial status; not authorized by EMA
- United StatesInvestigationalInvestigational New Drug (IND) application; no FDA approval
- United KingdomInvestigationalUnder clinical investigation; not licensed by MHRA
Never received regulatory approval in any jurisdiction. Phase II clinical development was conducted in Japan (Teikoku Hormone/Dainippon Sumitomo Pharma) and internationally. No active IND or ongoing pivotal trials are known as of the knowledge cutoff.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Soblidotin?
Soblidotin (TZT‑1027) is a synthetic analog of the marine peptide dolastatin 10. It acts as a potent antimitotic agent by disrupting microtubule dynamics and has been evaluated in early‑phase clinical trials for solid tumours.
What is Soblidotin used for?
Soblidotin is educationally associated with: Solid tumor oncology, Non-small cell lung cancer treatment, Antitubulin antineoplastic activity, ADC payload candidate, Soft tissue sarcoma treatment. Educational only — not medical advice.
How is Soblidotin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Soblidotin?
Reported adverse effects include: Peripheral neuropathy, Alopecia, Constipation, Nausea/vomiting, Neutropenia, Fatigue. This list is not exhaustive — consult a qualified clinician.
Who should avoid Soblidotin?
Recorded contraindications: Severe peripheral neuropathy, Severe hepatic impairment, Pregnancy, hypersensitivity to soblidotin or excipients. Consult a qualified clinician before use.